The Danish pharmaceutical company Novo Nordisk has announced promising early results for amycretin, a novel oral weight loss medication. This new drug appears to outperform the company’s highly successful injectable weight loss drug, Wegovy®. In a Phase I trial, participants who received amycretin lost 13.1% of their body weight over 12 weeks, compared to 1.1 % for participants in the placebo group. The results, which have not been published, suggest a significant advancement in obesity treatment options.
Needle-Free Option
Amycretin stands out not only for its efficacy but also for its administration method. Unlike Wegovy, which requires weekly injections, amycretin is taken orally once a day. This shift to a pill-based regimen could vastly improve patient compliance and comfort and represents a noteworthy development in the field of medical weight management.
The Science Behind Amycretin
Amycretin is a co-agonist of both a glucagon-like peptide-1 (GLP-1) and receptors for amylin, a hormone involved in regulating hunger. The drug’s dual-action approach may provide additive benefits and distinguish it from semaglutide, which Novo Nordisk markets as Wegovy and Ozempic®. Novo Nordisk, along with Eli Lilly and others, have been pursuing an oral drug option to provide an easier treatment regimen than the weekly injectables.
Putting Early Results in Context
While it is too early to make extensive comparisons, the amycretin Phase I results are promising. For context, Wegovy showed a 14.9% average weight reduction over 68 weeks in its STEP-1 clinical trial. Amycretin’s rapid achievement of significant weight loss at 12 weeks makes it a potentially faster-acting solution. Although extended trials will be necessary to fully understand its long-term efficacy and safety profile, the early trial results suggest that amycretin is safe and well-tolerated, with a similar side effect profile to semaglutide. Novo Nordisk announced plans to begin a larger Phase II trial in the next six months.
Novo Nordisk’s Expanding Anti-Obesity Pipeline
Novo Nordisk is not stopping at amycretin. The company is expanding its portfolio in the obesity and weight management sector, including initiating a Phase I trial for a monotherapy amylin molecule later this year. The company also has plans to move a tri-agonist into clinical trials within the next 12 months. In addition, Novo Nordisk is developing and testing CagriSema, a combination of semaglutide and cagrilintide, an amylin analog. The therapy is delivered in a weekly injection. These efforts suggest the company’s intention to lead the charge in developing obesity and weight management solutions.
Market Impact and Future Outlook
The news of these developments has already impacted Novo Nordisk’s market standing, with shares soaring by 8% following the announcement. This uptick clearly indicates the high expectations investors and the market have for Novo Nordisk’s innovative pipeline.
As the company ramps up its R&D, marked by a 35% increase in spending in 2023, all eyes will be on how these new treatments perform in ongoing and future studies. In addition to their effects when it comes to managing weight and regulating appetite, research will continue to explore the effects of anti-obesity drugs on a range of conditions, such as cardiovascular diseases, and further expand the number of indications for which these drugs are prescribed.
A Leap Forward in Obesity Treatment
Novo Nordisk, a long-time leader in the diabetes drug market, has shown its commitment to providing a range of treatments for obesity. With amycretin’s early success and other promising candidates in the pipeline, the future looks bright for new weight management solutions. As the landscape of obesity treatment evolves, Novo Nordisk’s innovative pipeline could redefine standards and expectations in the field.
Did you enjoy this blog post? Check out our other blog posts as well as related topics on our Webinar page.
QPS is a GLP- and GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, preclinical and clinical drug research development services. Since 1995, it has grown from a tiny bioanalysis shop to a full-service CRO with 1,100+ employees in the U.S., Europe and Asia. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine and clinical development. An award-winning leader focused on bioanalytics and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction and turnkey laboratories and facilities. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance and trusted service to its valued customers. For more information, visit www.qps.com or email info@qps.com.
